1. Volume 23, Issue 2, Pages 321-329 (February 2015)
Case–Control Estimation of the Impact of Oncolytic Adenovirus on the Survival of Patients With Refractory Solid Tumors 
Anna Kanerva, Anniina Koski, Ilkka Liikanen, Minna Oksanen, Timo Joensuu, Otto Hemminki, Juni Palmgren, Kari Hemminki, Akseli Hemminki 
Molecular Therapy 
Volume 23, Issue 2, Pages (February 2015)
DOI: /mt
Copyright © 2015 American Society of Gene & Cell Therapy Terms and Conditions

2. Figure 1
Cumulative survival data. Virus treated patients = black line, control patients = gray line. (a) All viral treatments pooled. (b) All patients treated with GMCSF-coding viruses. (c) Patient with GMCSF-sensitive cancer types and treatment with GMCSF-coding viruses. (d) Patients with WHO performance status 0 or 1. (e) Patients with good performance score (WHO 0 or 1), GMCSF-sensitive tumor types and treatment with a GMCSF-coding virus. (f) Subpopulation of patients with GMCSF-sensitive cancer types and treatment with CGTG-102 virus.
Molecular Therapy  , DOI: ( /mt )
Copyright © 2015 American Society of Gene & Cell Therapy Terms and Conditions

3. Figure 2
Patients with ovarian, fallopian tubal and primary peritoneal carcinomas. (a) Cumulative survival data of all ovarian cancer patients analyzed. Virus treated patients = black line, control patients = gray line. (b) Subgroup of ovarian cancer patients treated with CGTG-102 virus. (c) Grade 3 adverse events in ovarian cancer patients treated with oncolytic adenoviruses. (d) Clinical responses in ovarian cancer patients after viral treatments. (e) Overall survival of ovarian cancer patients with single or serial viral treatments. Serial treatment = black line, single treatment = gray line.
Molecular Therapy  , DOI: ( /mt )
Copyright © 2015 American Society of Gene & Cell Therapy Terms and Conditions